資訊列表
資訊列表
正(zheng)大制(zhi)藥(yao)集(ji)團(tuan)是中(zhong)(zhong)(zhong)(zhong)國(guo)(guo)領(ling)先的(de)創新研(yan)究和研(yan)發(fa)驅(qu)動型醫藥(yao)集(ji)團(tuan),產品包括多(duo)種生(sheng)(sheng)物藥(yao)和化學藥(yao),在(zai)腫(zhong)瘤、肝(gan)病、呼吸(xi)系統、外科/鎮(zhen)痛四大治療(liao)領(ling)域(yu)處于優勢地位。 集(ji)團(tuan)擁有(you)一(yi)家香(xiang)港(gang)上市公(gong)司——中(zhong)(zhong)(zhong)(zhong)國(guo)(guo)生(sheng)(sheng)物制(zhi)藥(yao)有(you)限(xian)公(gong)司,控(kong)股(gu)成(cheng)(cheng)(cheng)員企業(ye)20余家。公(gong)司于2000年(nian)在(zai)香(xiang)港(gang)聯交所(suo)上市,2013年(nian)入選MSCI全球(qiu)標準指(zhi)(zhi)(zhi)數之中(zhong)(zhong)(zhong)(zhong)國(guo)(guo)指(zhi)(zhi)(zhi)數成(cheng)(cheng)(cheng)分股(gu);2018年(nian)入選恒生(sheng)(sheng)指(zhi)(zhi)(zhi)數成(cheng)(cheng)(cheng)分股(gu);2019年(nian)入選恒生(sheng)(sheng)中(zhong)(zhong)(zhong)(zhong)國(guo)(guo)企業(ye)指(zhi)(zhi)(zhi)數成(cheng)(cheng)(cheng)分股(gu);2020年(nian)入選恒生(sheng)(sheng)滬深港(gang)通(tong)生(sheng)(sheng)物科技50指(zhi)(zhi)(zhi)數成(cheng)(cheng)(cheng)分股(gu)、恒生(sheng)(sheng)中(zhong)(zhong)(zhong)(zhong)國(guo)(guo)(香(xiang)港(gang)上市)25指(zhi)(zhi)(zhi)數。中(zhong)(zhong)(zhong)(zhong)國(guo)(guo)生(sheng)(sheng)物制(zhi)藥(yao)連續多(duo)年(nian)榮(rong)登(deng)美國(guo)(guo)權(quan)威(wei)雜志《制(zhi)藥(yao)經理人(ren)》發(fa)布(bu)的(de)“全球(qiu)制(zhi)藥(yao)企業(ye)TOP50”,連續三(san)年(nian)獲評(ping)《福(fu)布(bu)斯》(亞洲)“亞太最佳公(gong)司50強(qiang)”。
中國(guo)生物制(zhi)藥以(yi)仿制(zhi)為基石,向創新(xin)全面轉型,創新(xin)藥驅(qu)動增(zeng)長,收(shou)入占比逐年提(ti)升(sheng);內研管線驅(qu)動創新(xin)轉型,不斷(duan)提(ti)升(sheng)技術(shu)平臺;在頂尖科學團隊帶領(ling)下積極推動國(guo)際(ji)化進(jin)程,搶(qiang)占國(guo)際(ji)前沿賽道。公司將(jiang)秉承“健康(kang)科技,溫暖更(geng)多生命”的使命,專注創新(xin),服(fu)務病患,致(zhi)力于成為全球領(ling)先的制(zhi)藥企業。
